Tag Archives: clinical studies

How well do clinical studies take sex and gender differences into account?

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Silhouette of a couple walking

Photo: meltwater via Flickr

The history of inequity in medical studies is long and harrowing, and it continues today. But at least today, there is more awareness of the history and the present-day problems that persist. For example, the Endocrine Society recently released a scientific statement demanding more research into sex differences for the sake of public health.

The fact that males and females — not to mention individuals who do not identify as either binary category — do not respond the same way to different diseases, drugs and other interventions has been a relatively new development in the history of clinical trials. As recently as 1977, women of childbearing age were explicitly excluded by the FDA from phase 1 and 2 drug trials. In practice, that often extended to phase 3 trials and other types of studies for various reasons. Continue reading

New approach treats Alzheimer’s one person at a time

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic leader on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Photo: Iriss via Flickr

Can a precision medicine approach to Alzheimer’s disease (AD) and other dementias improve outcomes?

That is the theory behind the Dementia Prevention Initiative (DPI). The Florida Atlantic University (FAU) program twists the usual methods used to research and treat AD by employing an “n-of-1” design individualize medicine down to a single patient. Instead of conducting a conventional trial of 100 people who get the same treatment, the program conducts 100 single trials personalized to the individual. The youngest DPI patient is currently 61, and the oldest is 86. Continue reading